N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,370 Folic Acid and Zinc Supplementation Trial (FAZST)
Pregnancy · Live Birth · Spontaneous Abortion
Primary: Live Birth — 404; 416; 97; 91 Participants
Phase 2 N=10 Elagolix for Fertility Enhancement Clinical Trial
Endometriosis · Unexplained Infertility
Primary: Number of Live Births — 3; 1 live births
N/A N=20 Fertility Decision-Making in Youth and Young Adults
Transgender Adolescents & Young Adults
Primary: Change in Fertility-related Knowledge — 51.463; 67.073; 85.366; 93.171 score on a scale — p=<.001
N/A N=196 Effect of a Multivitamin Supplement With Probiotic (Seidivid Ferty4®) on Oocyte Retrieval and Quality
Reproductive Techniques, Assisted
Primary: Number of Oocytes Retrieved — 24.77; 22.57 oocytes retrieved — p=0.2629
Phase 3 N=52 A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
Infertility · Ovarian Stimulation
Primary: Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI) — 9.5 Metaphase II Oocytes
N/A N=28 Investigating the Physiological Effects of Weight Loss on Male Fertility
Male Infertility · Obesity · Weight Loss
Primary: Sperm Concentration — 53.6; 58.5; 20.1; 15 million sperms/mL
Phase 3 N=27 Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles
Oocyte Donation
Primary: Number of Patients Producing Anti-FSH Antibodies. — 0 participants
Phase 4 N=188 Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial
Infertility
Primary: Mean Fertilization Proportion (2PN/Oocytes Collected) — 0.63; 0.55 proportion of oocytes fertilized
N/A N=62 Reproductive Hormonal Alterations in Obesity
Obesity
Primary: Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1) — 4.1; 3.6 IU/L
Phase 2 N=520 Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
Infertility
Primary: Number of Fertilized Oocytes (2 Pronuclei [PN]) — 7.0; 8.7; 9.2; 6.7 2PN oocytes
Phase 3 N=1,011 Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women
Controlled Ovarian Simulation
Primary: Ongoing Pregnancy Rate — 31.3; 25.7 percentage of participants
Phase 3 N=372 Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment
Infertility
Primary: Number of Oocytes Retrieved (Per Protocol Population) — 10.8; 10.6 Number of retrieved oocytes — p=0.0003
Phase 4 N=310 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
Ovulation Induction
Primary: Percentage of Participants With a Mono-follicular Development — 56.55; 55.20 percentage of participants — p=0.9560
Phase 3 N=405 Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
Infertility
Primary: Number of Fertilized (2 Pronuclei [2PN]) Oocytes — 8.3; 6.7 Fertilized oocytes
Phase 3 N=108 A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment
Luteal Hormone Supplementation
Primary: The Proportion of Subjects With Blood Progesterone Concentration Not Less Than 10 ng/ml — 98.9 percentage of subjects
Phase 3 N=215 Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization
Infertility · Ovulation Induction · In-Vitro Fertilization
Primary: Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP) — 159 subjects
Phase 1 N=34 Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects
Healthy
Primary: Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC 0-t,Adj) for Follicle-Stimulating Hormone (FSH) — 3187.4…
Phase 4 N=15 Effect of hCG on Receptivity of the Human Endometrium
Infertility · Subfertility
Primary: Endometrial Staging in hCG Versus Vehicle Treated Patients — 4.0; 4.6; 3.9; 6.5 days — p=<0.05
Phase 3 N=1,332 Efficacy Study of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for Use in Human IVF
Infertility
Primary: Ongoing Implantation Rate Week 7 — 23.5; 20.0 percentage of transferred embryos
Phase 4 N=23 Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study
Infertility
Primary: Oocytes — 19; 47 oocytes
Phase 3 N=1,100 Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF
Infertility
Primary: Clinical Pregnancy Rate After One Cycle of Treatment - ITT Population — 114; 138; 435; 413 Participants
Phase 3 N=348 Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women
Infertility
Primary: Number of Oocytes Retrieved — 9.3; 10.5 Oocytes retrieved
Phase 3 N=379 Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility
Infertility, Female
Primary: Rate of Good Birth Outcomes — 23; 29 Participants — p=0.404
Phase 3 N=151 Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.
Infertility
Primary: Total Number of Oocytes Retrieved — 10.9; 12.0 oocytes
Phase 4 N=442 Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
Infertility
Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes
Phase 3 N=900 Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
Pregnancy · Unexplained Infertility
Primary: Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH. — 9; 8; 34 number of multiples
N/A N=395 Clearblue Advanced Fertility Monitor Consumer One Cycle at Home Study
Pregnancy
Primary: The Ability of the Volunteer to Use the New Clearblue Advanced Fertility Monitoring a Home Setting — 89.7 percentage of participants
Phase 2 N=20 RA-2 13-cis Retinoic Acid (Isotretinoin)
Male Infertility · Klinefelter's Syndrome · Y-chromosome Microdeletions
Primary: Millions of Sperm Per Ejaculate — 2.5; 3.8 Millions of sperm per ejaculate
Phase 3 N=588 Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)
Infertility, Female
Primary: Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of Controlled Ovarian Stimulation (COS)…